GSK 重返肿瘤领域初见回报，即将迎来第六款获批抗癌药
STAT+: GSK sees its return to cancer start to pay off
GSK 过去一周在肿瘤领域连获进展：一款抗癌药新增适应症获批，下一代化疗药物全球研究首批数据公布，授权引进的药物登上 ESMO 总统会议。公司还预计未来数周迎来一款肺癌新药的获批，届时将拥有第六款获批抗癌药。
The company could soon have its sixth approved cancer drug
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
MADRID — In the past week, a GSK cancer drug picked up an approval for another tumor type, the company unveiled the first data from a global study of a promising next-generation chemotherapy, and a medicine that the firm has licensed got the limelight in a presidential session at a major oncology conference here.
GSK is also awaiting another expected approval in the coming weeks, this time for a new lung cancer drug.
It’s a good run considering GSK was out of oncology a decade ago.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
-
Europe Correspondent
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
来源：STAT News · statnews.com